Exelixis Inc - Company Profile
Powered by 
All the data and insights you need on Exelixis Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Exelixis Inc Strategy Report
- Understand Exelixis Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Exelixis Inc (Exelixis) is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company’s pipeline product candidates include zanzalintinib, XB002 and XL102 for the treatment of advanced or metastatic solid tumors and CBX-12 for advanced metastatic refractory solid tumors. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.
Headquarters
United States of America
Address
1851 Harbor Bay Parkway, Alameda, California, 94502
Website
www.exelixis.com
Telephone
1 650 8377000
No of Employees
1,310
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EXEL (NASD)
Revenue (2022)
$1.8B
13.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
14%
(2022 vs 2021)
Market Cap*
$6.9B
Net Profit Margin (2022)
XYZ
0.4%
(2022 vs 2021)
* As of and is in US$
Exelixis Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Marketed: |
| Cometriq (cabozantinib) |
| Cabometyx (cabozantinib) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company partnered with Cybrexa Therapeutics and announced to regain all rights to CBX-12 (alphalex exatecan), to enhance the delivery of exatecan to tumor cells. |
| 2023 | Contracts/Agreements | In December, the company and Arcus Biosciences entered into a clinical trial collaboration for STELLAR-009. |
| 2023 | Others | In December, the company announced the initiation of STELLAR-305, a phase 2/3 pivotal trial evaluating zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck. |
Competitor Comparison
| Key Parameters | Exelixis Inc | Novartis AG | Amgen Inc | Aimmune Therapeutics Inc | Astex Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | Alameda | Basel | Thousand Oaks | Bridgewater | Pleasanton |
| State/Province | California | - | California | New Jersey | California |
| No. of Employees | 1,310 | 76,057 | 26,700 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stelios Papadopoulos, Ph.D. | Chairman | Executive Board | 1998 | 74 |
| Michael M. Morrissey, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2010 | 62 |
| Christopher J. Senner | Chief Financial Officer; Executive Vice President | Senior Management | 2015 | 55 |
| Amy Peterson, M.D | Chief Medical Officer; Executive Vice President - Product Development and Medical Affairs | Senior Management | 2023 | - |
| Dana T. Aftab, Ph.D. | Chief Scientific Officer; Executive Vice President - Discovery and Translational Research | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward